Patent Foramen Ovale

Publication Date: April 29, 2020

Key Points

Key Points

  • For patients with cryptogenic stroke and PFO, percutaneous PFO closure probably reduces the risk of stroke recurrence (HR-0.41, summary rate difference -0.67% per year), probably is associated with a periprocedural complication rate of 3.9%, and probably is associated with the development of serious non-periprocedural atrial fibrillation (RR-2.72, summary rate difference 0.33% per year).
  • For patients with cryptogenic stroke and PFO, anticoagulation medication and antiplatelet medication are possibly equally effective at reducing recurrent stroke.

Management

...nagement...

...ns Regarding Percutaneous PFO Closu...

...patients being considered for PFO c...

...ts being considered for PFO closure, clini...

...nts being considered for PFO closure, clini...

In patients being considered for PFO clos...

...ts being considered for PFO closure thought to be...

...patients being considered for PFO closu...

...patients being considered for PFO cl...

...tients being considered for PFO clo...

...dergoing PFO closure, patients should...

...k alternative mechanism of stroke is identifi...

...oing PFO closure, patients should be assess...

...th a PFO detected after stroke and no other et...

...ts younger than 60 years with a PFO and an em...

...ians may inform patients that presence...

...e may be offered in other populations, such...

...closure may be offered to younger patients (e....

...patient for whom PFO closure is being conside...


...mendations Regarding Medical Therapy

...nts who opt to receive medical therapy...

...who would otherwise be considered good...


Figure 1. Management Algorith...